Welcome!

News Feed Item

Augie's Quest To Transition from MDA to the ALS Therapy Development Institute

TUCSON, Ariz. and CAMBRIDGE, Mass., Jan. 30, 2014 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association (MDA) and Augie Nieto, co-chairman of MDA's ALS division together with his wife Lynne, today announced they are transitioning management of the successful "Augie's Quest" campaign from MDA to the ALS Therapy Development Institute (ALS TDI).  The transition will be occurring in the first quarter of 2014 as the organizations continue to support Augie's Quest initiatives.  MDA and ALS TDI will continue to support all currently scheduled Augie's Quest events.

(Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO)

Since 2005, Augie's Quest has raised nearly $40 million.  From these donations, MDA has funded research and drug development ventures at ALS TDI, which have enabled the Institute to lead the world in preclinical drug screening of potential treatments for ALS, advance a promising treatment into clinical trials, develop new animal and induced pluripotent stem cell models to advance others, and partner with several global biotechnology and pharmaceutical companies on other important ALS treatment development programs.

"Augie has done remarkable work to raise both awareness and funds to support ALS," said R. Rodney Howell, MD, chairman of MDA's board of directors.  "Because the funds are directed to ALS TDI through MDA's translational research grants program, it makes sense that the management of these operations be led by ALS TDI.  We are grateful for the past partnership and look forward to building on our shared progress for the larger ALS community."

"I have been working with the MDA since I was diagnosed with ALS.  It is a stellar organization.  The momentum we have built with Augie's Quest at ALS TDI requires a renewed and focused effort on increasing the amount of funds going to research and drug development. I call upon all my fellow PALS and the global ALS community to join me in accomplishing the task before us," said Nieto, who also serves as chairman of ALS TDI.

MDA has 44 ALS clinics directly assisting people fighting the disease and serves more ALS patients than any other U.S. nonprofit group, providing expert disease management, support groups and education, care coordination, and patient assistance.  After the transition, it will remain the largest non-profit funder of ALS research in America with about 50 different projects underway worldwide representing $15-million of MDA commitments. 

MDA's involvement with ALS began in the early 1950s when Eleanor Gehrig, widow of beloved Yankees first baseman Lou Gehrig, was searching for a way to fight the disease that had taken her husband's life. Mrs. Gehrig served more than a decade as MDA National Campaign Chairman.  Since then, MDA has invested more than $324 million to ALS research and health care services.

This decision will more closely align Augie's Quest fundraising efforts with ALS TDI. The world's first nonprofit biotech, ALS TDI is also the world's largest independent ALS-focused drug development organization. The Institute's internal R&D team of 30 industry-trained scientists collaborates with leaders from both biopharma and academia to discover and develop treatments for ALS.  ALS TDI has also emerged as the largest venture philanthropy investor with a focus on ALS.

About MDA
The Muscular Dystrophy Association is the world's leading nonprofit health agency dedicated to finding treatments and cures for muscular dystrophy, amyotrophic lateral sclerosis (ALS) and other neuromuscular diseases. It does so by funding worldwide research; by providing comprehensive health care services and support to MDA families nationwide; and by rallying communities to fight back through advocacy, fundraising and local engagement. Visit mda.org and follow us on Facebook at facebook.com/MDAnational and Twitter @MDAnews.

About ALS Therapy Development Institute (ALS TDI)
The mission of the ALS Therapy Development Institute (ALS TDI) is to discover and develop effective treatments to end ALS as soon as possible. ALS TDI is the world's largest independent ALS/MND drug development-focused nonprofit organization. It currently has partnerships with dozens of pharmaceutical and biotechnology companies worldwide in order to advance potential treatments into the clinic. Its lead ALS therapeutic candidate, Novartis' (Switzerland) Gilenya (TDI-132), is in Phase 2A clinical trial for ALS.  The 501c3 nonprofit biotech is funded and led by people living with ALS and their families. For more information, visit www.als.net.

SOURCE Muscular Dystrophy Association

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Customer experience has become a competitive differentiator for companies, and it’s imperative that brands seamlessly connect the customer journey across all platforms. With the continued explosion of IoT, join us for a look at how to build a winning digital foundation in the connected era – today and in the future. In his session at @ThingsExpo, Chris Nguyen, Group Product Marketing Manager at Adobe, will discuss how to successfully leverage mobile, rapidly deploy content, capture real-time d...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, wh...
IoT generates lots of temporal data. But how do you unlock its value? How do you coordinate the diverse moving parts that must come together when developing your IoT product? What are the key challenges addressed by Data as a Service? How does cloud computing underlie and connect the notions of Digital and DevOps What is the impact of the API economy? What is the business imperative for Cognitive Computing? Get all these questions and hundreds more like them answered at the 18th Cloud Expo...
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, will explore the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences betwee...
As cloud and storage projections continue to rise, the number of organizations moving to the cloud is escalating and it is clear cloud storage is here to stay. However, is it secure? Data is the lifeblood for government entities, countries, cloud service providers and enterprises alike and losing or exposing that data can have disastrous results. There are new concepts for data storage on the horizon that will deliver secure solutions for storing and moving sensitive data around the world. ...
Enterprise networks are complex. Moreover, they were designed and deployed to meet a specific set of business requirements at a specific point in time. But, the adoption of cloud services, new business applications and intensifying security policies, among other factors, require IT organizations to continuously deploy configuration changes. Therefore, enterprises are looking for better ways to automate the management of their networks while still leveraging existing capabilities, optimizing perf...
What a difference a year makes. Organizations aren’t just talking about IoT possibilities, it is now baked into their core business strategy. With IoT, billions of devices generating data from different companies on different networks around the globe need to interact. From efficiency to better customer insights to completely new business models, IoT will turn traditional business models upside down. In the new customer-centric age, the key to success is delivering critical services and apps wit...
The IoT is changing the way enterprises conduct business. In his session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, discuss how businesses can gain an edge over competitors by empowering consumers to take control through IoT. We'll cite examples such as a Washington, D.C.-based sports club that leveraged IoT and the cloud to develop a comprehensive booking system. He'll also highlight how IoT can revitalize and restore outdated business models, making them profitable...
The essence of data analysis involves setting up data pipelines that consist of several operations that are chained together – starting from data collection, data quality checks, data integration, data analysis and data visualization (including the setting up of interaction paths in that visualization). In our opinion, the challenges stem from the technology diversity at each stage of the data pipeline as well as the lack of process around the analysis.
Designing IoT applications is complex, but deploying them in a scalable fashion is even more complex. A scalable, API first IaaS cloud is a good start, but in order to understand the various components specific to deploying IoT applications, one needs to understand the architecture of these applications and figure out how to scale these components independently. In his session at @ThingsExpo, Nara Rajagopalan is CEO of Accelerite, will discuss the fundamental architecture of IoT applications, ...
Cloud-based NCLC (No-code/low code) application builder platforms empower everyone in the organization to quickly build applications and executable processes that broaden access, deepen collaboration, and enhance transparency for all team members. Line of business owners (LOBO) and operations managers know best their part of the business and their processes. IT departments are beginning to leverage NCLC platforms to empower and enable LOBOs to lead the innovation, transform the organization, an...
@DevOpsSummit taking place June 7-9, 2016 at Javits Center, New York City, and Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 18th International @CloudExpo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world.
SYS-CON Events announced today that ContentMX, the marketing technology and services company with a singular mission to increase engagement and drive more conversations for enterprise, channel and SMB technology marketers, has been named “Sponsor & Exhibitor Lounge Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York City, New York. “CloudExpo is a great opportunity to start a conversation with new prospects, but what happens after the...
SYS-CON Events announced today that MangoApps will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. MangoApps provides modern company intranets and team collaboration software, allowing workers to stay connected and productive from anywhere in the world and from any device. For more information, please visit https://www.mangoapps.com/.
SYS-CON Events announced today the Docker Meets Kubernetes – Intro into the Kubernetes World, being held June 9, 2016, in conjunction with 18th Cloud Expo | @ThingsExpo, at the Javits Center in New York, NY. Register for 'Docker Meets Kubernetes Workshop' Here! This workshop led by Sebastian Scheele, co-founder of Loodse, introduces participants to Kubernetes (container orchestration). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, participants learn ...